The Independent on MSN4mon
Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’
Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new ...
Nature1y
A new horizon in Alzheimer’s disease: targeting highly neurotoxic amyloid-β oligomers (AβOs)
By the early 1990s, the amyloid cascade hypothesis had emerged, proposing that AD is fundamentally caused by deposition of Aβ protein ... of cognitive decline. Donanemab (Eli Lilly), an amyloid ...
News Medical26d
Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?
New research shows that lecanemab and donanemab can slow cognitive decline ... samples for amyloid beta (Aβ) and tau protein assessment. All participants underwent clinical and cognitive ...